An evaluation of the cardiotoxicity of imatinib mesylate

被引：51

作者：

Ribeiro, Antonio Luiz ^{[1
,2
]}

Marcolino, Milena Soriano ^{[1
]}

Bittencourt, Henrique N. S. ^{[1
,3
]}

Barbosa, Marcia M. ^{[4
]}

Nunes, Maria do Carmo P. ^{[1
,2
]}

Xavier, Vitor Fonseca ^{[1
]}

Clementino, NeIrna C. D. ^{[1
,3
]}

机构：

[1] Univ Fed Minas Gerais, Hosp Clin, Sch Med, BR-30130100 Belo Horizonte, MG, Brazil

[2] Univ Fed Minas Gerais, Hosp Clin, Serv Cardiol, BR-30130100 Belo Horizonte, MG, Brazil

[3] Univ Fed Minas Gerais, Hosp Clin, Hematol Serv, BR-30130100 Belo Horizonte, MG, Brazil

[4] Hosp Socor, BR-30110075 Belo Horizonte, MG, Brazil

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 12期

关键词：

Imatinib; Cardiotoxicity; Chronic myeloid leukaemia; Ventricular function; BNP;

D O I：

10.1016/j.leukres.2008.03.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We studied 103 consecutive patients with chronic myeloid leukaemia on treatment with imatinib (IM) and 57 patients with chronic myeloproliferative disorders not treated with IM in order to evaluate its cardiotoxicity. There was no statistical difference regarding cardiac symptoms and signs, BNP levels and echocardiographic measurements for IM and control groups, except for peripheral oedema, more frequent in the IM group. Four patients in the IM group presented a BNP level >100 pg/ml, one of them with depressed LVEF. IM was not related to systematic deterioration of cardiac function, but there is still a possibility of isolated cases of cardiotoxicity. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1809 / 1814

页数：6

共 50 条

[21] A Multifaceted Evaluation of Imatinib-induced Cardiotoxicity in the Rat
Herman, Eugene H.
Knapton, Alan
Rosen, Elliot
Thompson, Karol
Rosenzweig, Barry
Estis, Joel
Agee, Sara
Lu, Quynh-Anh
Todd, John A.
Lipshultz, Steven
Hasinoff, Brian
Zhang, Jun
TOXICOLOGIC PATHOLOGY, 2011, 39 (07) : 1091 - 1106
[22] Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation
Hada, Nobuko
Netzer, William Joseph
Belhassan, Fanny
Wennogle, Lawrence Paul
Gizurarson, Sveinbjorn
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 102 : 46 - 54
[23] EVALUATION OF THE SAFETY OF IMATINIB MESYLATE IN PATIENTS WITH CHRONIC MEYLOID LEUKEMIA
Alwan, F.
Matti, F.
Alkassir, A.
Hussein, J.
HAEMATOLOGICA, 2012, 97 : 542 - 543
[24] A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor
Ben Ami, Eytan
Demetri, George D.
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 571 - 578
[25] The new era of imatinib mesylate
Ohyashiki, K
Goldman, J
LEUKEMIA RESEARCH, 2004, 28 : S1 - S1
[26] IMATINIB MESYLATE AND CARDIAC FUNCTION
Cerchione, C.
Luciano, L.
Cimmino, C.
Memoli, M.
Pane, F.
HAEMATOLOGICA, 2016, 101 : S100 - S100
[27] Imatinib mesylate induced erythroderma
Sanghavi, Swapnil A.
Dongre, Atul M.
Khopkar, Uday S.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2012, 78 (03):
[28] Imatinib Mesylate (Gleevec) Hepatotoxicity
Ayse L. Mindikoglu
Arie Regev
Pablo A. Bejarano
Enrique J. Martinez
Lennox J. Jeffers
Eugene R. Schiff
Digestive Diseases and Sciences, 2007, 52 : 598 - 601
[29] Effects of imatinib mesylate in osteoblastogenesis
Tibullo, Daniele
Giallongo, Cesarina
La Cava, Piera
Berretta, Salvatore
Stagno, Fabio
Chiarenza, Annalisa
Conticello, Concetta
Palumbo, Giuseppe A.
Di Raimondo, Francesco
EXPERIMENTAL HEMATOLOGY, 2009, 37 (04) : 461 - 468
[30] Cardiotoxic effects of imatinib mesylate
Kerkelä, R
Grazette, L
Force, T
CIRCULATION RESEARCH, 2005, 97 (02) : E23 - E23

← 1 2 3 4 5 →